Please provide your email address to receive an email when new articles are posted on . Postdischarge pharmacotherapy rates rose from 12.6% in 2014 to 23.9% in 2023 for ALD-related hospitalizations.

Despite decades of progress in reducing the prevalence of cigarette smoking, tobacco use remains a leading cause of preventable death and disease, and a significant driver of health care costs in the ...

Psychedelic therapy is a promising approach for tackling tobacco addiction, early results of a pilot clinical trial show in which psilocybin outperformed nicotine patches in helping smokers quit.

Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline ...

The National Cancer Institute (NCI) has awarded Chrono Therapeutics a Small Business Innovation Research (SBIR) grant of up to $2.3 million for product development of the digital portion of the ...